West China Hospital Rare Diseases: Multisystem and Specialist Assessment

What the rare disease center actually is

West China Hospital created its rare disease center in July 2016 and reorganized it in 2021 as the Rare Disease Diagnosis and Research Center, according to a March 2022 institutional feature. The description matters for patients: the center is presented as an organizing structure for multidisciplinary clinics, complex multisystem case conferences, disease cohorts and laboratory platforms, not as a single department that treats every rare diagnosis.

That distinction shapes what a patient can reasonably expect. A rare disease often crosses specialties, and the center's role is to connect the relevant expertise around one case. The 2022 feature describes genomics, proteomics and metabolomics platforms supporting this work, and names cohorts including idiopathic pulmonary hypertension, ALS and systemic sclerosis. These are documented directions, not a complete list of conditions assessed.

The same feature records institutional recognition: a 2020 Huaying award from the hospital and, in 2021, the first Golden Snail Rare Disease Medical Contribution Award. It also notes a 2018 collaboration with Birmingham in joint health and biomedical informatics. Treat these as dated institutional facts, not as evidence that any particular patient will be accepted or diagnosed.

Neurological genetics and movement disorders

Professor Shang Huifang's official academic biography describes clinical and basic research in neurogenetic and degenerative disease and movement disorders, including motor neurone disease and Parkinson's disease and dementia. Her contribution to the hospital's neurology genetics, ALS and rare disease academic group is documented, alongside editorial work.

One caution belongs here. Research into inherited forms of Parkinson's disease or dementia does not make every Parkinson's or dementia diagnosis a rare disease. A patient asking about this direction should be clear whether the question concerns a known genetic cause, an early-onset or familial pattern, or a more typical degenerative diagnosis. The receiving neurologist decides what assessment is appropriate.

Her documented honors include recognition as a Sichuan academic and technical leader, a health leading talent designation and Tianfu Famous Doctor, plus inclusion in the 2023 Elsevier China Highly Cited Researchers list. These are dated academic distinctions. They do not establish current overall leadership of the rare disease center, and the biography should not be read as listing present offices.

Amyloidosis: a documented multisystem clinic

A September 2018 hospital description of the amyloidosis multidisciplinary clinic shows how the center model looks in practice. Amyloidosis involves abnormal protein deposits that can affect different organs, so the clinic combined hematology, nephrology, cardiology, radiology and ultrasound. The description names Wu Yu, Zhu Huanling and Niu Ting from hematology, Hu Zhangxue and Zhong Hui from nephrology, and Chen Yucheng and Zhang Qing from cardiology as participants at that date.

For a patient, the useful point is the organizing logic: cardiac, kidney and blood involvement may need to be assessed together rather than sequentially by unrelated clinics. The 2018 roster is a historical record, not a confirmed 2026 team list, so anyone planning around this clinic should ask which specialties currently participate and how a case is routed.

This is a dated example of a multisystem clinic, not a current team roster or a diagnostic checklist. A patient can ask how the established amyloidosis diagnosis or unresolved organ-related question would be reviewed and which specialties would contribute. The receiving clinicians would need to explain what can be assessed from existing records and what remains uncertain.

Fabry disease and early-stage gene therapy research

Fabry disease is an X-linked lysosomal storage disorder that can affect multiple organs, which places it naturally within a multisystem assessment model. A March 2025 hospital report describes a Phase I/II study of ZS805, a recombinant adeno-associated virus gene therapy candidate for Fabry disease, led by Chen Yucheng in cardiology and rare disease work. The candidate was developed by Dong Biao's team at a biotherapy laboratory, following earlier investigator-initiated research.

This is investigational early clinical research, not routine approved therapy or an offer of enrollment. A report that a candidate has entered a study does not establish a personal treatment option. For a patient already diagnosed with Fabry disease, the preliminary question is what assessment the clinical team can provide and how it would distinguish established care from research.

Chen Yucheng's role in this study also illustrates the connection between clinical specialties and laboratory development. Dong Biao's team developed the candidate, while the reported clinical study was led through cardiology and rare-disease work. Those are different research responsibilities. They should not be interpreted as a promise that a new patient can receive the candidate or see a particular investigator.

Education, professional organization and why they matter to patients

At a meeting held from 31 July to 1 August 2020, Shang Huifang was elected first chair of the Sichuan Medical Association's rare-disease committee, Chen Yucheng chair-elect and Liu Yi vice chair. The hospital's report documents a cross-specialty academic organization and training activity. These are dated roles, not confirmation of every current office.

A February 2023 book launch reported by the hospital adds an education dimension. Cheng Nansheng and Shang Huifang co-chief-edited Clinical Rare Disease Diagnosis and Treatment Tutorial, published by People's Medical Publishing House for residents and young physicians, with case-based learning across neurological, immune and multisystem topics and collaboration with other academic centers. This is physician education, not an international patient protocol.

For patients, these facts suggest a department that invests in structured teaching and cross-specialty discussion. They do not tell you which clinician will see you, how quickly a diagnosis will be reached, or whether a remote review is possible. Those remain case-specific questions for the hospital.

Specialty standing and how to read it

The hospital's rare-disease specialty placed fourth in the Fudan 2023 national specialty reputation list. This is a historical institutional reference, not a ranking of neurological genetics, amyloidosis or Fabry assessment. Those directions need to be considered separately when explaining the purpose of an enquiry. A center's reputation does not establish a diagnosis or select a treatment for an individual.

An assessment request may concern a confirmed rare diagnosis, an unresolved diagnostic question or coordination across several specialties. State which of those is intended. The documented multidisciplinary structure is relevant because it connects specialties, cohorts and research platforms; the receiving team must still decide which disciplines could contribute to the individual question and what information is needed.

Practical questions before planning an assessment

Summarize what has already been assessed, which specialties have been involved and the main unresolved decision. Ask which existing reports should be supplied, what language or format is required and whether a records-based opinion is possible before travel. The hospital should confirm its proposed next step. Urgent or worsening problems need local care rather than waiting for an international enquiry.

ChinaSpecialistCare can help organise a rare-disease enquiry, prepare records and coordinate assessment arrangements after hospital acceptance. We are independent of the hospital and cannot guarantee a diagnosis, named clinician or treatment outcome. A brief initial enquiry is free; an optional proxy consultation is not a prerequisite.

Rare disease assessment and care planning